Premium
Is the risk of morbidity and rare mortality worth the cure?
Author(s) -
D'Angio G. J.,
Clatworthy H. W.,
Evans A. E.,
Newton W. A.,
Tefft M.
Publication year - 1978
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(197801)41:1<377::aid-cncr2820410151>3.0.co;2-#
Subject(s) - medicine , intensive care medicine , cure rate , clinical trial , modalities , treatment modality , cancer , cancer treatment , surgery , social science , sociology
Many more children with cancer are being cured, often as a result of aggressive treatment regimens. These employ several modalities and multiple chemotherapeutic agents. The acute complications resulting from this type of treatment are relatively well known. Those that develop later are becoming better understood; some are formidable. The challenge in pediatric oncology lies in developing better treatment strategies with a view to minimizing normal tissue damage while achieving higher cure rates. The cooperative clinical trial mechanism is well‐suited to testing new treatment regimens designed to achieve these goals.